CJC-1295
Also known as: CJC-1295, CJC-1295 DAC, Mod GRF 1-29
A long-acting growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to produce more growth hormone. Often paired with a ghrelin mimetic for synergistic GH release.
Last updated
Mechanism of Action
CJC-1295 is a modified GHRH (1-29) analog that binds the GHRH receptor on pituitary somatotrophs, stimulating endogenous growth hormone synthesis and release. The DAC (Drug Affinity Complex) version adds a lysine linker that binds serum albumin, dramatically extending half-life and prolonging GH and IGF-1 elevation. It preserves the natural pulsatile pattern of GH release rather than producing a constant supraphysiologic level.
- Half-life
- DAC version: ~6-8 days; without DAC (Mod GRF 1-29): ~30 minutes
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Increases endogenous growth hormone and IGF-1 levels
- Long half-life allows infrequent administration (DAC version)
- Supports lean body mass and fat metabolism
- May improve sleep quality and recovery
- Preserves natural pulsatile GH secretion
- Synergizes strongly with ghrelin mimetics like ipamorelin
Potential Side Effects
- Water retention and tingling/numbness in extremities
- Injection-site irritation
- Headache or flushing
- Transient increases in hunger or fatigue
- Potential impact on insulin sensitivity with prolonged use
Common Dosing
Research literature references the DAC form around 1-2 mg weekly, while the no-DAC form is studied at ~100 mcg per dose 1-3 times daily timed to GH pulses. Educational ranges only.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active malignancy (GH/IGF-1 stimulation)
- Diabetic retinopathy or uncontrolled diabetes
- Pregnancy or breastfeeding
- Not approved for human therapeutic use
Ipamorelin
A selective ghrelin receptor agonist (growth hormone secretagogue) prized for stimulating GH release with minimal effect on cortisol or prolactin. Considered one of the gentler GH peptides.
GHRP-2
A growth hormone releasing peptide that strongly stimulates GH secretion via the ghrelin receptor. More potent than GHRP-6 with somewhat less appetite stimulation.
GHRP-6
An early growth hormone releasing peptide best known for strong GH stimulation alongside a pronounced increase in appetite via ghrelin signaling.
CJC-1295 / Ipamorelin Blend
The most popular GH-peptide combination, pairing a GHRH analog (CJC-1295) with a selective ghrelin agonist (ipamorelin) to produce a strong, clean, synergistic growth hormone pulse.
- View
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
2006
- View
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
2005
- View
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
2006
- View
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
2009